In the clinic, a signature of NOTCH4 with its downstream targets HES and HEY predicts poor response and poor prognosis in two-independent ER + ve BC cohorts; in vivo, the acquired tamoxifen-resistance of PDX is reversed along with reductions of BCSCS when NOTCH4 function was inhibited [76]. Here, NOTCH4 is linked to breast cancer.